Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Acoramidis Hydrochloride

FDA-approved product (tablet, oral), marketed as Attruby.

Registered studies
5
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Acoramidis Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Amyloidosis
  • Cardiomyopathy
  • Male infertility

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cardiac preparations
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

5registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Acoramidis Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Acoramidis Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

    NCT07116473 · start 2026-11

    Registered record
    Registry ID
    NCT07116473
    Conditions
    Amyloidosis in Transthyretin (TTR); Amyloidosis, Familial; Amyloid Cardiomyopathy; Amyloid Cardiomyopathy, Transthyretin-Related; Amyloidogenic Transthyretin (ATTR) Amyloidosis; Heart Disease; Cardiomyopathies; Amyloidosis, Hereditary, Transthyretin-Related; Polyneuropathies; Amyloidosis
    Interventions
    Acoramidis (AG10)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2037-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis in Transthyretin (TTR); Amyloidosis, Familial; Amyloid Cardiomyopathy; Amyloid Cardiomyopathy, Transthyretin-Related +6 more
    InterventionAcoramidis (AG10)
    PhasePhase 3
    Registry statusNot yet recruiting

  • Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

    NCT07695701 · start 2026-07

    Registered record
    Registry ID
    NCT07695701
    Conditions
    Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis
    Interventions
    Acoramidis (AG10) oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-07
    Completion
    2030-11
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloidosis Cardiomyopathy (ATTR-CM); Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis
    InterventionAcoramidis (AG10) oral tablet
    PhasePhase 4
    Registry statusRecruiting

  • Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

    NCT07306949 · start 2025-10-01

    Registered record
    Registry ID
    NCT07306949
    Conditions
    Transthyretin-type Cardiac Amyloidosis
    Interventions
    Acoramidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-10-01
    Completion
    2028-03-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin-type Cardiac Amyloidosis
    InterventionAcoramidis
    PhasePhase 4
    Registry statusRecruiting

  • Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

    NCT06563895 · start 2025-05-12

    Registered record
    Registry ID
    NCT06563895
    Conditions
    Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis; Cardiomyopathies; Heart Diseases; Polyneuropathies
    Interventions
    Acoramidis; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-05-12
    Completion
    2032-12
    Enrolment
    587

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis; Cardiomyopathies +2 more
    InterventionAcoramidis; Placebo oral tablet
    PhasePhase 3
    Registry statusRecruiting

  • Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

    NCT03860935 · start 2019-03-19

    Registered record
    Registry ID
    NCT03860935
    Conditions
    Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis; Cardiomyopathies; Heart Diseases
    Interventions
    acoramidis; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-03-19
    Completion
    2023-05-11
    Enrolment
    632

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis; Cardiomyopathies +1 more
    Interventionacoramidis; Placebo Oral Tablet
    PhasePhase 3
    Registry statusCompleted